Navigation Links
Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
Date:7/22/2009

trategic National Stockpile for emergency use in the treatment of inhalation anthrax.

"We are proud of our progress, but it is important to acknowledge that raxibacumab would never have been developed without Project BioShield," said James H. Davis, Ph.D., J.D., Executive Vice President and General Counsel, HGS, and leader of the Company's raxibacumab program with the U.S. Government. "It is widely known that anthrax spores can be aerosolized and turned into a bioterrorist weapon with the potential to cause significant loss of life. With raxibacumab, the United States now has a treatment for inhalation anthrax. It has taken HGS nearly seven years of work, much of it in close partnership with BARDA, to reach the point where we have successfully delivered raxibacumab to the Stockpile and secured this second purchase order. We are delighted to have reached this important milestone, and we look forward to continuing to work closely with BARDA in the interest of our nation's security."

Raxibacumab represents a new way to address the anthrax threat. While antibiotics can kill the anthrax bacteria, they are not effective against the deadly toxins that the bacteria produce. Raxibacumab targets anthrax toxins after they are released by the bacteria into the blood and tissues. In an inhalation anthrax attack, people may not know they are infected with anthrax until the toxins already are circulating in their blood, and it may be too late for antibiotics alone to be effective.

About the Raxibacumab Contract with the U.S. Government

Raxibacumab is being developed under a contract entered into with BARDA in 2006 (Contract Number HHS010020050006C). The order announced today is the second order received under the BARDA contract. HGS recognized $153.8 million in revenue in the first quarter of 2009 from the first delivery of raxibacumab to the Strategic National Stockpile, and wil
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... RESEARCH TRIANGLE PARK, N.C. , Aug. 27, ... reports on the decision by FedEx, UPS and ... shipments of certain biological specimens classified as ,select ... expertise and long history of handling these sensitive ... network, knowledge of global transportation regulations, trained and ...
(Date:8/26/2015)... MO (PRWEB) , ... August 26, 2015 , ... ... it is increasing its investment in the development and manufacture of highly valued ... The company’s scientific team's extensive expertise with protein chemistry has led to ...
(Date:8/26/2015)... HONG KONG , Aug. 26, 2015 ... "Company"), China,s leading provider of ... and stem cell storage services, today announced that the ... Holdings Limited ("MO2"), an entity wholly owned by Mr. ... the Company, has acquired the outstanding shares (the "Shares") ...
(Date:8/25/2015)... SHANGHAI , Aug. 25, 2015   WuXi ... open-access R&D capability and technology platform company serving the ... Holdings Ltd. ("Lee,s Pharm," Hong Kong Exchange Stock Code: ... Hong Kong with 20 years of operations ... the two companies have signed an agreement whereby WuXi,s ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... a groundbreaking film starring the top equine veterinarians whose ... May 28 Today the Foundation for Biomedical Research ... won a Telly Award in the 30th Annual Telly ... the premier award honoring outstanding local, regional, and cable ...
... Growth Opportunities in Increasing Food Productivity, Decreasing Dependence on ... May 28 DuPont (NYSE: DD ) ... addressing major global market trends, said DuPont CEO Ellen ... Kullman said the company,s research and development efforts are ...
... Inc. today announced that the Company,s product candidate, NT-501, ... Phase 2 clinical trials for retinitis pigmentosa ... the progressive degeneration of rod & cone photoreceptor cells ... peripheral vision and eventually leads to blindness. RP is ...
Cached Biology Technology:The Foundation for Biomedical Research Wins Telly Award for Majestic 2DuPont Innovation Addressing Major Global Market Trends 2DuPont Innovation Addressing Major Global Market Trends 3DuPont Innovation Addressing Major Global Market Trends 4Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 2Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 3Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 4Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 5
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... new sales campaign for Q4 2015. The new marketing ... team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) ... Group is a leader in retail driven marketing and ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... biological terms this question could involve a feedback loop that ... on that information. Although feedback loops are essential and they ... an organ such as the liver to detect if it ... and if it needs to regenerate itself. When such loops ...
... safe procedures for a promising experimental brain-cancer therapy which uses ... For many, this will conjure images of Spiderman's nemesis, ... science fiction, but rather to help to develop a promising ... the yellow Israeli scorpion preferentially attaches to the cells of ...
... Integrated Microbial Genomes (IMG) data management system of the U.S. ... released to the public. IMG 1.5 now contains a total ... and 259 bacterial phages) of which 602 are finished and ... finished and 100 draft genomes sequenced by DOE JGI, bringing ...
Cached Biology News:Study finds how organs monitor themselves during early development 2Study finds how organs monitor themselves during early development 3Study finds how organs monitor themselves during early development 4Radioactive scorpion venom for fighting cancer 2DOE JGI releases IMG 1.5 with curated archaeal genomes 2
... for covering tissue sections and cell preparations immunohistochemically ... insoluble end products. UltraMount Plus can ... or AEC that require an aqueous mounting medium, ... No heating is required prior to use. This ...
... Intracellular (IC) Fixation Buffer, used in ... No. 00-8333), can be used to ... performing intracellular staining of cytokines and ... solutions have been specially formulated for ...
Cytofix Buffer 100 mls...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Biology Products: